原因不明脳卒中の若年患者における卵円孔開存後の抗血栓治療の中止 (HALTI)
原因不明の脳卒中を有する若年患者における卵円孔開存後の抗血栓治療の中止。ハルティトライアル
To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.
調査の概要
詳細な説明
Young patients with a cryptogenic ischemic event undergoing transcatheter PFO closure exhibit a low but clinically relevant risk of bleeding (overall and major bleeding) at long-term follow-up, eventually exceeding the risk of ischemic events.
Importantly, the vast majority of major bleeding events seem to occur in patients receiving antiplatelet therapy. Preliminary data suggest that antiplatelet therapy discontinuation is not associated with any increase in ischemic events, and could potentially translate into a lower rate of major bleeding events at longer term follow-up. We therefore hypothesize that in young patients without any other comorbidities increasing the risk of stroke, shorter-term (≤1 year instead of lifelong) antiplatelet treatment could be a safe option following PFO closure.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Melanie Cote, MSc
- 電話番号:14186537270
- メール:melanie.cote@criucpq.ulaval.ca
研究連絡先のバックアップ
- 名前:Josep Rodes-Cabau, MD
- 電話番号:4186568711
- メール:josep.rodes@criucpq.ulaval.ca
研究場所
-
-
Quebec
-
Québec、Quebec、カナダ、G1V 4G5
- 募集
- IUCPQ
-
コンタクト:
- Melanie Cote, MSc
- 電話番号:Rodes-Cabau 4186568711
- メール:josep.rodes@criucpq.ulaval.ca
-
コンタクト:
- Josep Rodes-Cabau, MD
- 電話番号:4186568711
- メール:josep.rodes@criucpq.ulaval.ca
-
主任研究者:
- Josep Rodes-Cabau, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Successful transcatheter PFO closure with any approved device
- Patients ≤60 years diagnosed with a cryptogenic stroke/TIA who have undergone successful transcatheter PFO closure
Exclusion Criteria:
->60 year-old
- RoPE score <6
- Residual shunt ≥moderate following PFO closure
- Atrial fibrillation following PFO closure
- Presence of ≥2 cardiovascular risk factors (smoking, hypertension, dyslipidemia)
- Diabetes mellitus
- Thrombophilia (factor V Leiden, factor II mutation, anticardiolipin antibodies, lupus anticoagulant, anti-b2 glycoprotein-I antibodies, protein C deficiency, protein S deficiency)
- Recurrent cerebrovascular event (stroke, TIA) within the year following PFO closure
- Failure to provide signed informed consent
- Absolute contraindications for an MRI study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Antiplatelet treatment discontinuation
At 12 months post-PFO closure, patients will discontinue the antiplatelet treatment. All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure. |
All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Presence of new stroke events
時間枠:12 months
|
1)Acute episode of a focal or global neurological deficit with at least one of the following: change in level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphasia or aphasia, hemianopia, amaurosis fugax or other new neurological symptom(s) consistent with stroke.(2)Duration of a focal or global neurological deficit ≥ 24 hours OR < 24 hours if available neuroimaging documents a new hemorrhage or infarct; OR the neurological deficit results in death. |
12 months
|
|
Presence of new ischemic lesions
時間枠:24-month follow-up
|
Evaluated by MRI |
24-month follow-up
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of new cerebral ischemic lesions
時間枠:24-month follow-up
|
Evaluated by MRI |
24-month follow-up
|
|
Volume of new cerebral ischemic lesions
時間枠:24-month follow-up
|
Evaluated by MRI |
24-month follow-up
|
|
Number of ischemic events
時間枠:24-month follow-up
|
Stroke, TIA |
24-month follow-up
|
|
Number of ischemic events
時間枠:3-year follow-up
|
Stroke, TIA |
3-year follow-up
|
|
Number of ischemic events
時間枠:4-year follow-up
|
Stroke, TIA |
4-year follow-up
|
|
Number of ischemic events
時間枠:5-year follow-up
|
Stroke, TIA |
5-year follow-up
|
|
Number of ischemic events
時間枠:6-year follow-up
|
Stroke, TIA |
6-year follow-up
|
|
Number of ischemic events
時間枠:7-year follow-up
|
Stroke, TIA |
7-year follow-up
|
|
Number of ischemic events
時間枠:8-year follow-up
|
Stroke, TIA |
8-year follow-up
|
|
Number of ischemic events
時間枠:9-year follow-up
|
Stroke, TIA |
9-year follow-up
|
|
Number of ischemic events
時間枠:10-year follow-up
|
Stroke, TIA |
10-year follow-up
|
|
Rate of bleeding
時間枠:24-month follow-up
|
Life-threatening, major or minor bleeding |
24-month follow-up
|
|
Rate of bleeding
時間枠:3-year follow-up
|
Life-threatening, major or minor bleeding |
3-year follow-up
|
|
Rate of bleeding
時間枠:4-year follow-up
|
Life-threatening, major or minor bleeding |
4-year follow-up
|
|
Rate of bleeding
時間枠:5-year follow-up
|
Life-threatening, major or minor bleeding |
5-year follow-up
|
|
Rate of bleeding
時間枠:6-year follow-up
|
Life-threatening, major or minor bleeding |
6-year follow-up
|
|
Rate of bleeding
時間枠:7-year follow-up
|
Life-threatening, major or minor bleeding |
7-year follow-up
|
|
Rate of bleeding
時間枠:8-year follow-up
|
Life-threatening, major or minor bleeding |
8-year follow-up
|
|
Rate of bleeding
時間枠:9-year follow-up
|
Life-threatening, major or minor bleeding |
9-year follow-up
|
|
Rate of bleeding
時間枠:10-year follow-up
|
Life-threatening, major or minor bleeding |
10-year follow-up
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。